HOXA-AS2 and hepatocellular carcinoma: HOXA-AS2 was significantly down-regulated in 4 cell lines out of 5 (HA22T/VGH, ACHN, CRBM 1990 and HCC 1937) treated with sorafenib compared to DMSO-treated cells (Fig. 2I–K).